The National Comprehensive Care Network, an alliance of 21 of the world's leading cancer centers, released new guidelines for the treatment of blood cancers at the NCCN annual conference. Included in the updated guidelines is a recommendation for Campath (alemtuzumab), German drug major Bayer's treatment for chronic lymphocytic leukemia, as a first-line therapy for high-risk CLL patients 70 years old and above.
These are the latest in a series of clinical recommendations recognizing the importance of personalized medicine in CLL. Over the past few years, the NCCN treatment guidelines have shifted due to advances in clinical knowledge about diagnostic markers and targeted therapies, allowing physicians to personalize treatment for each patient and improve outcomes. These guidelines support the notion that individualized therapy is the future of CLL treatment and other blood cancers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze